Patents by Inventor Jeffrey Daniel Cohen
Jeffrey Daniel Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230234960Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: ApplicationFiled: March 15, 2023Publication date: July 27, 2023Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL, Jennifer Anne MCMAHON
-
Patent number: 11634426Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: GrantFiled: September 2, 2021Date of Patent: April 25, 2023Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
-
Publication number: 20210403480Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: ApplicationFiled: September 2, 2021Publication date: December 30, 2021Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL, Jennifer Anne MCMAHON
-
Patent number: 11117902Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: GrantFiled: May 18, 2020Date of Patent: September 14, 2021Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
-
Publication number: 20210260052Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.Type: ApplicationFiled: July 11, 2019Publication date: August 26, 2021Inventors: Jeffrey Daniel COHEN, Daniel Jon SALL
-
Publication number: 20200347073Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: ApplicationFiled: May 18, 2020Publication date: November 5, 2020Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL
-
Patent number: 10759786Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.Type: GrantFiled: May 31, 2017Date of Patent: September 1, 2020Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
-
Patent number: 10654866Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: GrantFiled: July 11, 2019Date of Patent: May 19, 2020Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall
-
Publication number: 20200017516Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: ApplicationFiled: July 11, 2019Publication date: January 16, 2020Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL
-
Publication number: 20190161477Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.Type: ApplicationFiled: May 31, 2017Publication date: May 30, 2019Inventors: Jolie Anne BASTIAN, Jiehao CHEN, Jeffrey Daniel COHEN, James Robert HENRY, William Thomas MCMILLEN, Bradley Earl REAMAN, Almudena RUBIO, Daniel Jon SALL, Gaiying ZHAO
-
Patent number: 9872853Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.Type: GrantFiled: May 31, 2017Date of Patent: January 23, 2018Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
-
Publication number: 20170354641Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.Type: ApplicationFiled: May 31, 2017Publication date: December 14, 2017Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
-
Patent number: 8507490Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.Type: GrantFiled: November 5, 2009Date of Patent: August 13, 2013Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
-
Publication number: 20110263602Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.Type: ApplicationFiled: November 5, 2009Publication date: October 27, 2011Applicant: ELI LILLY AND COMPANYInventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
-
Patent number: 7101891Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1Type: GrantFiled: March 27, 2002Date of Patent: September 5, 2006Assignee: Eli Lilly and CompanyInventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
-
Patent number: 6992097Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.Type: GrantFiled: June 3, 2003Date of Patent: January 31, 2006Assignee: Eli Lilly and CompanyInventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
-
Patent number: 6939946Abstract: A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.Type: GrantFiled: September 30, 2003Date of Patent: September 6, 2005Assignee: Eli Lilly and CompanyInventors: Peter Stanley Borromeo, Jeffrey Daniel Cohen, George Stuart Gregory, Stacy Kay Henle, Stephen Andrew Hitchcock, Louis Nickolaus Jungheim, Daniel Ray Mayhugh, Timothy Alan Shepherd, William Wilson Turner, Jr.
-
Publication number: 20040122234Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.Type: ApplicationFiled: June 3, 2003Publication date: June 24, 2004Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
-
Publication number: 20040116460Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.Type: ApplicationFiled: September 25, 2003Publication date: June 17, 2004Inventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
-
Patent number: 6743794Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).Type: GrantFiled: May 21, 2002Date of Patent: June 1, 2004Assignee: Eli Lilly and CompanyInventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang